Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Merle Ruberg »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Meriem Tazir < Merle Ruberg < Miao Cai  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000275 (2008) Agnès Camuzat [France] ; Marc Romana ; Alexandra Dürr [France] ; Josué Feingold [France] ; Alexis Brice [France] ; Merle Ruberg [France] ; Annie Lannuzel [France]The PSP‐associated MAPT H1 subhaplotype in Guadeloupean atypical Parkinsonism
000300 (2008) Annie Lannuzel [France] ; Merle Ruberg [France] ; Patrick P. Michel [France]Atypical parkinsonism in the Caribbean island of Guadeloupe: Etiological role of the mitochondrial complex I inhibitor annonacin
000397 (2005) Pierre Champy [France] ; Alice Melot [France] ; Vincent Guérineau Eng [France] ; Christophe Gleye [France] ; Djibril Fall [France, Sénégal] ; Gunter U. Höglinger [France] ; Merle Ruberg [France] ; Annie Lannuzel [France] ; Olivier Laprévote [France] ; Alain Laurens [France] ; Reynald Hocquemiller [France]Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe
000403 (2005) Günter U. Höglinger [France] ; Patrick P. Michel [France] ; Pierre Champy [France] ; Jean Feger [France] ; Etienne C. Hirsch [France] ; Merle Ruberg [France] ; Annie Lannuzel [France]Experimental evidence for a toxic etiology of tropical parkinsonism
000465 (2002) Annie Lannuzel [France] ; Patrick P. Michel [France] ; Dominique Caparros-Lefebvre [France] ; Jacqueline Abaul ; Reynald Hocquemiller ; Merle Ruberg [France]Toxicity of Annonaceae for dopaminergic neurons: Potential role in atypical parkinsonism in Guadeloupe
000671 (1989) Agid [France] ; Pascale Cervera [France] ; Etienne Hirsch [France] ; France Javoy-Agid [France] ; Stéphane Lehericy [France] ; Rita Raisman [France] ; Merle Ruberg [France]Biochemistry of Parkinson's disease 28 years later: A critical review

List of associated KwdEn.i

Nombre de
documents
Descripteur
5Humans
4Guadeloupe (epidemiology)
4Parkinsonism
3Guadeloupe
3Nervous system diseases
3Parkinsonian Disorders (etiology)
2Acetogenins
2Animals
2Mitochondria
2Neurons (drug effects)
2Neurotoxin
2Parkinson disease
2Parkinsonian Disorders (epidemiology)
2acetogenin
2mitochondria
2neurotoxin
2progressive supranuclear palsy
1Adenosine Triphosphate (metabolism)
1Aged
1Alkaloids (toxicity)
1Annona (chemistry)
1Annona (toxicity)
1Annonaceae
1Annonaceae (adverse effects)
1Annonaceae (chemistry)
1Annonaceae (toxicity)
1Antiparkinson Agents (antagonists & inhibitors)
1Antiparkinson Agents (therapeutic use)
1Apoptosis (drug effects)
1Atypical
1Brain (cytology)
1Brain (drug effects)
1Case-Control Studies
1Cell Culture Techniques
1Cell culture
1Cells, Cultured
1Chi-Square Distribution
1Chromatography, High Pressure Liquid (methods)
1Dopamine (metabolism)
1Dopamine Plasma Membrane Transport Proteins
1Dopaminergic neuron
1Drug Resistance
1Electron Transport Complex I (antagonists & inhibitors)
1Etiology
1European Continental Ancestry Group
1Fatty Alcohols (adverse effects)
1Fatty Alcohols (analysis)
1Fatty Alcohols (chemistry)
1Fatty Alcohols (toxicity)
1Female
1Furans (administration & dosage)
1Gabaergic neuron
1Gene Frequency
1Genotype
1Human
1Immunohistochemistry
1Lactones (administration & dosage)
1Lactones (adverse effects)
1Lactones (analysis)
1Lactones (chemistry)
1Lactones (toxicity)
1Levodopa (antagonists & inhibitors)
1Levodopa (therapeutic use)
1Linkage Disequilibrium
1MALDI MS
1Male
1Membrane Glycoproteins
1Membrane Transport Proteins (drug effects)
1Mesencephalon (drug effects)
1Mesencephalon (pathology)
1Middle Aged
1Mitochondria (drug effects)
1Mitochondria (metabolism)
1Mitochondrial Diseases (complications)
1Mitochondrial Diseases (etiology)
1Molecular Weight
1Nerve Tissue Proteins
1Neurons (metabolism)
1Pacific Islands
1Parkinson's disease
1Parkinsonian Disorders (complications)
1Parkinsonian Disorders (drug therapy)
1Parkinsonian Disorders (genetics)
1Parkinsonian Disorders (pathology)
1Plant Extracts (adverse effects)
1Plant Extracts (analysis)
1Plant Extracts (chemistry)
1Polymorphism
1Polymorphism, Single Nucleotide (genetics)
1Rats
1Risk factor
1Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (methods)
1Supranuclear Palsy, Progressive (complications)
1Supranuclear Palsy, Progressive (genetics)
1Toxicity
1annonacin
1apoptosis
1atypical parkinsonian syndromes
1atypical parkinsonism
1genetic polymorphism

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Merle Ruberg" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Merle Ruberg" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Merle Ruberg
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024